342 related articles for article (PubMed ID: 15255794)
1. What is the best size descriptor to use for pharmacokinetic studies in the obese?
Green B; Duffull SB
Br J Clin Pharmacol; 2004 Aug; 58(2):119-33. PubMed ID: 15255794
[TBL] [Abstract][Full Text] [Related]
2. Effect of obesity on the pharmacokinetics of drugs in humans.
Hanley MJ; Abernethy DR; Greenblatt DJ
Clin Pharmacokinet; 2010; 49(2):71-87. PubMed ID: 20067334
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
Sparreboom A; Wolff AC; Mathijssen RH; Chatelut E; Rowinsky EK; Verweij J; Baker SD
J Clin Oncol; 2007 Oct; 25(30):4707-13. PubMed ID: 17947717
[TBL] [Abstract][Full Text] [Related]
4. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007.
McLeay SC; Morrish GA; Kirkpatrick CM; Green B
Clin Pharmacokinet; 2012 May; 51(5):319-30. PubMed ID: 22439649
[TBL] [Abstract][Full Text] [Related]
5. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
Pai MP
Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the Relationship Between Lean Liver Volume and Fat-Free Mass.
Sinha J; Duffull SB; Green B; Al-Sallami HS
Clin Pharmacokinet; 2020 Apr; 59(4):475-483. PubMed ID: 31583612
[TBL] [Abstract][Full Text] [Related]
7. A standard weight descriptor for dose adjustment in the obese patient.
Duffull SB; Dooley MJ; Green B; Poole SG; Kirkpatrick CM
Clin Pharmacokinet; 2004; 43(15):1167-78. PubMed ID: 15568893
[TBL] [Abstract][Full Text] [Related]
8. The impact of obesity on the pharmacology of medications used for cardiovascular risk factor control.
Sankaralingam S; Kim RB; Padwal RS
Can J Cardiol; 2015 Feb; 31(2):167-76. PubMed ID: 25661551
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
11. The effect of body weight on dalteparin pharmacokinetics. A preliminary study.
Yee JY; Duffull SB
Eur J Clin Pharmacol; 2000 Jul; 56(4):293-7. PubMed ID: 10954342
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
[TBL] [Abstract][Full Text] [Related]
13. Glucocorticoids dosing in obese subjects: A systematic review.
Delaleu J; Destere A; Hachon L; Declèves X; Lloret-Linares C
Therapie; 2019 Sep; 74(4):451-458. PubMed ID: 30928086
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2014 Aug; 53(8):753-62. PubMed ID: 24989061
[TBL] [Abstract][Full Text] [Related]
15. The impact of obesity and disease on busulfan oral clearance in adults.
Gibbs JP; Gooley T; Corneau B; Murray G; Stewart P; Appelbaum FR; Slattery JT
Blood; 1999 Jun; 93(12):4436-40. PubMed ID: 10361142
[TBL] [Abstract][Full Text] [Related]
16. What is the best size predictor for dose in the obese child?
Anderson BJ; Holford NH
Paediatr Anaesth; 2017 Dec; 27(12):1176-1184. PubMed ID: 29076211
[TBL] [Abstract][Full Text] [Related]
17. Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD.
Morse JD; Cortinez LI; Anderson BJ
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36836174
[TBL] [Abstract][Full Text] [Related]
18. Propofol Sedation for Intragastric Balloon Removal: Looking for the Optimal Body Weight Descriptor.
Tsaousi G; Fyntanidou B; Stavrou G; Papakostas P; Kotzampassi K; Grosomanidis V
Obes Surg; 2019 Dec; 29(12):3882-3890. PubMed ID: 31290110
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass").
Shibutani K; Inchiosa MA; Sawada K; Bairamian M
Anesthesiology; 2004 Sep; 101(3):603-13. PubMed ID: 15329584
[TBL] [Abstract][Full Text] [Related]
20. Dosing of neuromuscular blocking agents in patients with obesity: A narrative review.
Erstad BL; Barletta JF
Anaesth Intensive Care; 2021 Mar; 49(2):98-104. PubMed ID: 33906465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
